Skip to content

Study · Randomized controlled trial · n = 51 · 2022

5 results

Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study.

Santos LPA, Bonduki CE, Dardes RCM, Heinke T, Patriarca MT

Clinics (Sao Paulo, Brazil)1 Oct 2022Cited by 5 (Europe PMC)

PMID36194923 (opens in a new tab)PMCIDPMC9531039 (opens in a new tab)DOI10.1016/j.clinsp.2022.100116 (opens in a new tab)PepBankPUB-36194923
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

ObjectivesIn this pilot, prospective, randomized, double-blind study, the authors compared the efficacy of oxytocin with promestriene in improving vaginal atrophy of Genitourinary Syndrome of Menopause (GSM).MethodsA total of 51 postmenopausal women with symptoms of GSM were evaluated. They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.ResultsAfter the use of the medications, both groups showed significant improvement in the three evaluated FSFI domains (p < 0.05) and there was no significant difference between the groups (p > 0.05). On clinical examination, the medications improved all the evaluated parameters but without statistical significance (p > 0.05). The evaluation of the thickness of the vaginal epithelium showed that both treatments led to increase in the vaginal epithelium (p < 0.05); however, the efficacy of promestriene was higher than that of oxytocin (p < 0.05).ConclusionsBoth medications were effective, however, studies with larger samples and longer follow-ups are needed to confirm the clinical applicability.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with genitourinary syndrome of menopause, FSFI domain improvements with oxytocin did not differ significantly from promestriene.

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin and promestriene gave similar improvements in sexual function scores.

    Peptide
    Oxytocin
    Outcome
    No significant changeFSFI domains, oxytocin versus promestriene
    Study

    n = 51

    Comparator
    Promestriene
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 90 daysAs given in this study (human).

    Source sentences

    Summary
    there was no significant difference between the groups (p > 0.05).
    2 context sentences
    Summary · context
    A total of 51 postmenopausal women with symptoms of GSM were evaluated.
    Summary · context
    They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with genitourinary syndrome of menopause, oxytocin increased vaginal epithelium thickness less than promestriene (p < 0.05).

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin thickened the vaginal lining less than promestriene did.

    Peptide
    Oxytocin
    Outcome
    DecreaseVaginal epithelium thickness, oxytocin versus promestriene
    Study

    n = 51

    Comparator
    Promestriene
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 90 daysAs given in this study (human).

    Source sentences

    Summary
    however, the efficacy of promestriene was higher than that of oxytocin (p < 0.05).
    2 context sentences
    Summary · context
    A total of 51 postmenopausal women with symptoms of GSM were evaluated.
    Summary · context
    They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with genitourinary syndrome of menopause, oxytocin improved all three evaluated FSFI domains after 90 days (p < 0.05).

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin improved sexual function scores after 90 days compared with before treatment.

    Peptide
    Oxytocin
    Outcome
    IncreaseFSFI domains (lubrication, satisfaction, pain) change
    Study

    n = 25

    Comparator
    Baseline (before treatment)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 90 daysAs given in this study (human).

    Source sentences

    Summary
    After the use of the medications, both groups showed significant improvement in the three evaluated FSFI domains (p 0.05).
    2 context sentences
    Summary · context
    A total of 51 postmenopausal women with symptoms of GSM were evaluated.
    Summary · context
    They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with genitourinary syndrome of menopause, the clinical examination parameters improved with the medications but without statistical significance.

    In plain wordsIn postmenopausal women with vaginal atrophy, exam findings improved with the medications, but the change was not statistically significant.

    Peptide
    Oxytocin
    Outcome
    No significant changeClinical visual examination parameters
    Study

    n = 25

    Comparator
    Baseline (before treatment)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 90 daysAs given in this study (human).

    Source sentences

    Summary
    On clinical examination, the medications improved all the evaluated parameters but without statistical significance (p > 0.05).
    2 context sentences
    Summary · context
    A total of 51 postmenopausal women with symptoms of GSM were evaluated.
    Summary · context
    They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with genitourinary syndrome of menopause, oxytocin increased vaginal epithelium thickness (p < 0.05).

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin increased the thickness of the vaginal lining compared with before treatment.

    Peptide
    Oxytocin
    Outcome
    IncreaseVaginal epithelium thickness
    Study

    n = 25

    Comparator
    Baseline (before treatment)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 90 daysAs given in this study (human).

    Source sentences

    Summary
    The evaluation of the thickness of the vaginal epithelium showed that both treatments led to increase in the vaginal epithelium (p < 0.05)
    2 context sentences
    Summary · context
    A total of 51 postmenopausal women with symptoms of GSM were evaluated.
    Summary · context
    They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.